ライフサイエンスコーパス: norepinephrine

1 eurotransmitter noradrenaline (also known as norepinephrine).

2 ruleus (LC) is the major source of forebrain norepinephrine.

3 for catecholamines and a turn-on response to norepinephrine.

4 pil dilations (PDR) were monitored to assess Norepinephrine.

5 eptic shock requiring more than 5 mug/min of norepinephrine.

6 eceptor activation by the endogenous agonist norepinephrine.

7 smitters, including L-DOPA, epinephrine, and norepinephrine.

8 ylguanidine (MIBG), a guanethidine analog of norepinephrine.

9 al to 2 mmol/L, randomized to vasopressin or norepinephrine.

10 ments of related neuromodulators dopamine or norepinephrine.

11 ance the synaptic levels of serotonin and/or norepinephrine.

12 o catalyze the synthesis of epinephrine from norepinephrine.

13 lls, produce catecholamines, epinephrine and norepinephrine.

14 agal balance correlated directly with plasma norepinephrine.

15 in Ca(2+) transients, which are sensitive to norepinephrine.

16 ly disturbed or absent in patients receiving norepinephrine.

17 glutamate but are relatively insensitive to norepinephrine.

18 Norepinephrine (93%) was the most common vasopressor.

19 be further enhanced by the administration of norepinephrine, a known activator of NCC.

20 increases sympathetic innervation and local norepinephrine accumulation.

21 cesses, possibly related to tonic and phasic norepinephrine activity.

22 gic receptor from astroglia, indicating that norepinephrine acts directly on these ubiquitous glial c

23 Norepinephrine adjusts sensory processing in cortical ne

24 tive evidence suggests the efficacy of early norepinephrine administration during resuscitation; howe

25 Median time from emergency room arrival to norepinephrine administration was significantly shorter

26 Among patients with septic shock receiving norepinephrine, administration of selepressin, compared

27 (defect of the positron emission tomography norepinephrine analog (11)C-hydroxyephedrine), lack of a

28 017) uncover how octopamine, an invertebrate norepinephrine analog, modulates the neural pathways tha

29 similarity and the ability to interact with norepinephrine and a number of compounds that bind with

30 administration of beta-adrenergic agonists (norepinephrine and CL-316243).

31 ute SCI in mice induced suppression of serum norepinephrine and concomitant increase in cortisol, des

32 onstrate input-specific interactions between norepinephrine and CRF, and point to an action by which

33 tered behaviors are associated with elevated norepinephrine and dopamine turnover in the striatum.

34 While both norepinephrine and epinephrine mostly inhibit the angiog

35 e > 2 mmol/L) differ from vasopressin versus norepinephrine and mortality in Vasopressin and Septic S

36 e and exercise performance, increased plasma norepinephrine and N-terminal pro-B-type natriuretic pep

37 luence target tissues by releasing primarily norepinephrine and NPY.

38 d by mechanisms that include increased fetal norepinephrine and reduced IGF-1 and insulin.

39 c and antidepressant-like effects, increased norepinephrine and serotonin levels and decreased nuclea

40 efense.Objectives: To investigate effects of norepinephrine and the alternative vasopressor vasopress

41 ere stimulated in the presence or absence of norepinephrine and vasopressin.

42 e-related peptide, endothelin-1, gentamicin, norepinephrine and vasopressin.

43 icity tests of pharmaceutical drugs, such as Norepinephrine and Verapamil was achieved with excellent

44 Both norepinephrine and withdrawal symptoms could be elicited

45 (1D), high-dose insulin therapy (1D-2D), and norepinephrine and/or epinephrine (1D).

46 uired in BAT for the thermogenic response to norepinephrine, and depletion of SREBP prevented mainten

47 is, the role of catecholamines (epinephrine, norepinephrine, and dopamine) is of interest due to thei

48 recursor for the neurotransmitters dopamine, norepinephrine, and epinephrine.

49 n of mouse kidney slices with isoproterenol, norepinephrine, and parathyroid hormone similarly increa

50 target monoamine transporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respe

51 the plasmalemmal transporters for dopamine, norepinephrine, and serotonin act either as competitive

52 s study, we examined the effect of dopamine, norepinephrine, and serotonin on lOFC neuronal excitabil

53 levated levels of stress hormones, including norepinephrine; and are resistant to the extinction of f

54 hormonal systems activated in heart failure (norepinephrine, angiotensin II, aldosterone, and neprily

55 The actions of norepinephrine are profoundly altered by recreational dr

56 ctate measurement during first hospital day, norepinephrine as first vasopressor, and avoidance of st

57 ients were assigned to either vasopressin or norepinephrine as first-line vasopressor therapy.

58 ial in septic shock (VANISH [Vasopressin vs. Norepinephrine as Initial Therapy in Septic Shock]).

59 uartile 1, 2.8; 95% CI, 2.1-3.7) and receive norepinephrine as initial vasopressor (adjusted odds rat

60 68.3% had lactate measured and 64% received norepinephrine as initial vasopressor.

61 septic shock.Measurements and Main Results: Norepinephrine attenuated the production of proinflammat

62 est UFP and O(3) levels increases peripheral norepinephrine availability through decreased clearance

63 l window of opportunity for locus coeruleus/ norepinephrine-based therapeutics exists.

64 ts for the cofactor (SAM) and the substrate (norepinephrine) binding sites.

65 In a control group of patients receiving norepinephrine but not vasopressin infusion for treatmen

66 tative increases in presynaptic dopamine and norepinephrine by tyrosine administered before condition

67 also conferred region-specific resilience to norepinephrine changes.

68 validity and generalizability beyond classic norepinephrine circuits because it simplifies extremely

69 HPG) and norepinephrine levels, a marker for norepinephrine clearance, was reduced with UFP + O(3).

70 nse may have perturbed pulmonary endothelial norepinephrine clearance.

71 t hypothesis was that the vasopressin versus norepinephrine comparison and 28-day mortality of patien

72 compared dopamine transients in the NAc with norepinephrine concentration changes in the vBNST, and c

73 CHADN eliminated norepinephrine content in the liver and partially decrea

74 ng also increases adipose tissue sympathetic norepinephrine content.

75 euromodulators, including hypocretin/orexin, norepinephrine, corticotropin-releasing factor, and cyto

76 ct targets such as astrocytes, which exhibit norepinephrine-dependent Ca(2+) elevations during vigila

77 le injection of LPS (2 mg/kg) or a selective norepinephrine depleting toxin DSP-4 (50 mg/kg), then th

78 However, for both dopamine and norepinephrine, differences depended on the Galphai/o pr

79 Furthermore, we observed reduced levels of norepinephrine, dopamine or serotonin, mainly in the bra

80 k twice, with and without methylphenidate, a norepinephrine-dopamine reuptake inhibitor.

81 oronary percutaneous intervention (PCI), and norepinephrine dose, the mean +/- SD post-arrival increm

82 Norepinephrine dose-response curves showed no HTN-relate

83 alpha-2 agonist dexmedetomidine may decrease norepinephrine doses in septic shock.

84 set of measurements including hemodynamics, norepinephrine doses, and depth of sedation were obtaine

85 light the potential of adrenergic stress and norepinephrine-driven beta-AR signaling to regulate the

86 roinflammatory cytokine balance.Conclusions: Norepinephrine dysregulates the immune response in mice

87 Transgenic mouse models showed that norepinephrine dysregulation after LC lesions exacerbate

88 In LPS-challenged volunteers, norepinephrine enhanced plasma IL-10 concentrations and

89 The sensor results in punctate staining of norepinephrine-enriched chromaffin cells visualized usin

90 we examined its influence on brain levels of norepinephrine, epinephrine, dopamine, serotonin and the

91 her 24-hour cumulative vasopressor dosing as norepinephrine equivalent (beta coefficient, 0.37; 95% C

92 irst 24 hours of shock onset was 8.5 mug/min norepinephrine equivalents (3.4-18.1 mug/min norepinephr

93 ncomitant vasopressor requirements, based on norepinephrine equivalents excluding vasopressin, were s

94 0; 95% CI, -7.8 to -2.2 hours; total dose in norepinephrine equivalents median, 17.7 mg vs 26.4 mg; d

95 norepinephrine equivalents (3.4-18.1 mug/min norepinephrine equivalents).

96 sopressor doses from 0.75 to 0.31 mcg/kg/min norepinephrine equivalents.

97 ssor dose infused across all vasopressors in norepinephrine equivalents.

98 In parallel, it suppressed urinary norepinephrine excretion, and induced c-Fos expressions

99 ession, encoding the enzyme that synthesizes norepinephrine from dopamine, with downregulation observ

100 via the reuptake of dopamine, serotonin and norepinephrine from extra-neuronal regions and thus main

101 hours was significantly higher in the early norepinephrine group (118/155 [76.1%] vs. 75/155 [48.4%]

102 ation was significantly shorter in the early norepinephrine group (93 vs. 192 min; P < 0.001).

103 pressin group and 66 patients (52.8%) in the norepinephrine group (p = 0.52).

104 We compared vasopressin-to-norepinephrine group 28- and 90-day mortality in Vasopre

105 between groups: 24/155 (15.5%) in the early norepinephrine group versus 34/155 (21.9%) in the standa

106 The early norepinephrine group was associated with lower incidence

107 ic enhancement, dopamine (bromocriptine) and norepinephrine (guanfacine) manipulations did not improv

108 We then measured extinction-retention, norepinephrine, HDAC4, and HDAC5.

109 al research suggests that the neuromodulator norepinephrine helps to maintain selective attention.

110 (corticotropin-releasing factor, dynorphin, norepinephrine, hypocretin, vasopressin, glucocorticoids

111 Vasopressin lowered mortality versus norepinephrine if lactate was less than or equal to 2 mm

112 valuating the hypothesis that early low-dose norepinephrine in adults with sepsis with hypotension in

113 stress on gene expression, and (2) enhancing norepinephrine in brain regions regulating cognitive eff

114 028) lower mortality with vasopressin versus norepinephrine in lactate less than or equal to 2 mmol/L

115 line vasopressor therapy was not superior to norepinephrine in reducing 28-day mortality rate.

116 cal microscopy indicating that it stains the norepinephrine in secretory vesicles.

117 in28a, whereas knocking down Pck2 attenuated norepinephrine-induced cardiac hypertrophy.

118 Aneurysms and rupture did not occur with norepinephrine-induced hypertension.

119 KCNK3 antagonizes norepinephrine-induced membrane depolarization by promot

120 There is no evidence that norepinephrine induces local "hotspots": Norepinephrine

121 Norepinephrine infusion during cecal ligation and punctu

122 Care Unit 2 (n=203), and Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock st

123 er assessed in the VASST (Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock Tr

124 The relationship between the norepinephrine infusion rate and the use of beta-blocker

125 Multivariable analyses adjusted for age and norepinephrine infusion rate demonstrated that the combi

126 In patients, higher norepinephrine infusion rates were correlated with a mor

127 eep fetuses following a 7-day noradrenaline (norepinephrine) infusion.

128 Concealed vasopressin (0.03 U/min.) or norepinephrine infusions.

129 effects) model proposes that local glutamate-norepinephrine interactions enable "winner-take-more" ef

130 Norepinephrine is thought to play a key role in this pro

131 Octopamine, the invertebrate analog of norepinephrine, is known to modulate a large variety of

132 er subcutaneous injection with vehicle, 1 mg norepinephrine/kg, or 5 mg AITC/kg.

133 stress response, as are the locus coeruleus norepinephrine (LC-NE) and dorsal raphe serotonin (DR 5-

134 Plasma lipid panel and norepinephrine level were also measured.

135 ts displayed progressive loss of hippocampal norepinephrine levels and locus coeruleus fibres in the

136 noradrenergic fiber sprouting and normalized norepinephrine levels in the spleen, indicating that hei

137 ween plasma dihydroxyphenylglycol (DHPG) and norepinephrine levels, a marker for norepinephrine clear

138 onomic failure phenotype had very low plasma norepinephrine levels, slow resting heart rate, no REM s

139 ovolemia and increased levels of circulating norepinephrine levels.

140 hat norepinephrine induces local "hotspots": Norepinephrine mainly decreases evoked responses; facili

141 These results suggest that the LC-norepinephrine may be pivotal to understand links betwee

142 levate dopamine in addition to serotonin and norepinephrine, may demonstrate greater efficacy, with t

143 complex and heterogeneous actions including norepinephrine mechanisms related to higher cognitive ci

144 ld mu-opioid receptor agonism, serotonin and norepinephrine mediated nociception modulation, and N-me

145 ntral sTNFalpha signaling drives peripheral, norepinephrine-mediated organ dysfunction, a novel mecha

146 e investigated relationships between central norepinephrine metabolism, tau and beta-amyloid (Abeta),

147 eus innervation and deficits locus coeruleus/norepinephrine modulated behaviours, does not exist, ham

148 We here show that the neuromodulator norepinephrine modulates olfactory bulb spontaneous acti

149 35 patients (mechanical ventilation n = 78; norepinephrine n = 13).

150 were randomly divided into two groups: early norepinephrine (n = 155) and standard treatment (n = 155

151 Here we investigated whether norepinephrine (NE) administration into the basolateral

152 f neuromodulation by acetylcholine (ACh) and norepinephrine (NE) and afferent synaptic excitation.

153 tissue (AT) function through the release of norepinephrine (NE) and beta adrenergic signaling.

154 s catecholamine transmission via blockade of norepinephrine (NE) and dopamine (DA) reuptake transport

155 LC-derived norepinephrine (NE) can stimulate neuroprotective mechan

156 Diffuse neuromodulatory systems such as norepinephrine (NE) control brain-wide states such as ar

157 Both epinephrine (EPI) and norepinephrine (NE) could directly inhibit breast cancer

158 Norepinephrine (NE) has been shown to influence sensory,

159 nd to be suppressed with decreased levels of norepinephrine (NE) in brains of infected animals and in

160 Norepinephrine (NE) is a key biogenic monoamine neurotra

161 Norepinephrine (NE) is produced primarily by neurons in

162 rizing aqueous solution of dopamine (DA) and norepinephrine (NE) monomers for generating polycatechol

163 alient stimuli; and the locus coeruleus (LC)-norepinephrine (NE) neuromodulatory system, which mediat

164 Dysregulated norepinephrine (NE) neurotransmission is associated with

165 Norepinephrine (NE) plays a central role in the acquisit

166 deficits depend, in part, on stress-induced norepinephrine (NE) release in the basolateral amygdala

167 ion, a noninvasive marker of arousal-related norepinephrine (NE) release, while concurrently recordin

168 We wondered why norepinephrine (NE) that differs from dopamine only for

169 cessed by the physiological neurotransmitter norepinephrine (NE) via an Oct3 organic cation transport

170 hesis of the catecholamines - dopamine (DA), norepinephrine (NE), and epinephrine (EP).

171 leus (LC) neurons, the source of hippocampal norepinephrine (NE), are activated by novelty and change

172 that the human catecholamine stress hormone, norepinephrine (NE), facilitates Fe acquisition in Spn u

173 Norepinephrine (NE), via alpha1A ARs, activated a small

174 cellular mechanism(s) linking macrophages to norepinephrine (NE)-mediated regulation of thermogenesis

175 ocus coeruleus (LC), the source of forebrain norepinephrine (NE).

176 autoinducer-3 (AI-3), epinephrine (Epi), and norepinephrine (NE).

177 m, whose chief effector is the catecholamine norepinephrine (NE).

178 tion of three important biomolecules such as norepinephrine (NEP), melatonin (MEL) and nicotine (NIC)

179 amines serotonin (SERT), dopamine (DAT), and norepinephrine (NET) are targets of multiple psychoactiv

180 A), serotonin (5-HT), epinephrine (Epn), and norepinephrine (Norepn), using square wave voltammetry (

181 For example, the invertebrate counterpart of norepinephrine, octopamine, and its biological precursor

182 lude or separate the physiological effect of norepinephrine on core body temperature, the fast increa

183 ming tactile discrimination tasks through LC-norepinephrine optimization of thalamic sensory processi

184 pamine or the D2 agonist quinpirole, but not norepinephrine or serotonin, was prevented by the GABAA

185 nset of shock and were randomized to receive norepinephrine or vasopressin followed by hydrocortisone

186 BL/6J mice received a continuous infusion of norepinephrine or vasopressin via microosmotic pumps and

187 these profiles influenced response to either norepinephrine or vasopressin, or to corticosteroids in

188 MAP target (n = 58) received higher doses of norepinephrine (p = 0.004) and dobutamine (p = 0.01) and

189 hock who were receiving more than 0.2 mug of norepinephrine per kilogram of body weight per minute or

190 ctopamine (OA, the invertebrate homologue of norepinephrine), plays a major role in controlled sugar

191 ost frequent comparator was a combination of norepinephrine plus dobutamine.

192 hydroxymandelic acid (DHMA), a metabolite of norepinephrine produced by E. coli, is a chemoattractant

193 eceptor agonists isoproterenol, epinephrine, norepinephrine, prostaglandin (PG) E(2), PGD(2), and ade

194 , P < 0.0001) were positively associated and norepinephrine (r(2) = 0.59, P < 0.0001) was negatively

195 Modeling confirmed norepinephrine regulation of intrathalamic circuit dynam

196 e important role of alpha2AAR in controlling norepinephrine release and response, this novel regulati

197 ary sensory input to the brain by modulating norepinephrine release from the locus coeruleus into the

198 timulation of LC-NE fibers in the BLA evokes norepinephrine release in the basolateral amygdala (BLA)

199 eurons, resulting in reduced firing rate and norepinephrine release.

200 an effect that can be reversed by enhancing norepinephrine release.

201 ol suppresses their activation by inhibiting norepinephrine release.

202 Both circulating epinephrine and norepinephrine released from adrenal medullary chromaffi

203 from adrenal medullary chromaffin cells and norepinephrine released locally from sympathetic nerve t

204 itially started on hemodialysis despite high norepinephrine requirements and ultimately transitioned

205 Norepinephrine requirements decreased from 0.69 +/- 0.72

206 rgic agonists have been reported to decrease norepinephrine requirements in experimental septic shock

207 t chemotaxis response of Escherichia coli to norepinephrine requires that it be converted to 3,4-dihy

208 ne transients in the NAc, but did not elicit norepinephrine responses in the vBNST.

209 etermine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an a

210 s with depression and treated with serotonin-norepinephrine reuptake inhibitor (N = 424) we show that

211 venlafaxine-extended release (serotonin and norepinephrine reuptake inhibitor [SNRI]) therapy.

212 Extensive global use of the serotonin-norepinephrine reuptake inhibitor Amitriptyline (AMI) fo

213 tions for a selective serotonin or serotonin-norepinephrine reuptake inhibitor between conception and

214 antidepressant, is a selective serotonin and norepinephrine reuptake inhibitor in humans, and this dr

215 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor prescription before or

216 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor use and 11 studies rep

217 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor users, but uncertainty

218 the antidepressant efficacy of the serotonin/norepinephrine reuptake inhibitor venlafaxine in male mi

219 ed with treatment outcomes for the serotonin norepinephrine reuptake inhibitor venlafaxine.

220 iamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promo

221 mfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting ef

222 eceptor agonist, opioid antagonist, dopamine-norepinephrine reuptake inhibitor, and glucagon-like pep

223 ssant venlafaxine, a selective serotonin and norepinephrine reuptake inhibitor, is present in surface

224 fluoxetine but not desipramine, a selective norepinephrine reuptake inhibitor, observed in condition

225 uptake inhibitors or selective serotonin and norepinephrine reuptake inhibitors (126 RCTs in 3 system

226 Serotonin-norepinephrine reuptake inhibitors (SNRIs) significantly

227 tonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and placebo

228 otonin reuptake inhibitors [SSRI], serotonin-norepinephrine reuptake inhibitors [SNRI], tricyclic ant

229 elated antidepressants [TCAs], serotonin and norepinephrine reuptake inhibitors [SNRIs], and other an

230 nin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic or

231 Serotonin-norepinephrine reuptake inhibitors also appear to be eff

232 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors are among the most co

233 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors in critically ill pat

234 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors previously or during

235 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors were continued in ICU

236 to patients taking other opioids, serotonin-norepinephrine reuptake inhibitors, and drugs affecting

237 serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors.

238 d smoking cessation aid, blocks dopamine and norepinephrine reuptake transporters and noncompetitivel

239 e dopamine-dense nucleus accumbens (NAc) and norepinephrine-rich ventral bed nucleus of the stria ter

240 To determine whether Norepinephrine routinely reports the statistical structu

241 NS510 is the highest affinity fluorescent norepinephrine sensor currently available and can be use

242 ve neurotransmitters (dopamine, epinephrine, norepinephrine, serotonin, and histamine) and preventing

243 tals that demonstrated at least 1 quarter of norepinephrine shortage in 2011, norepinephrine use amon

244 ion between admission to a hospital during a norepinephrine shortage quarter and in-hospital mortalit

245 Hospital-level norepinephrine shortage was defined as any quarterly (3-

246 c shock in US hospitals affected by the 2011 norepinephrine shortage, the most commonly administered

247 eption, monoamines (dopamine, serotonin, and norepinephrine) signal via metabotropic receptors.

248 ta support reciprocal roles for dopamine and norepinephrine signaling during drug exposure and withdr

249 etic approaches, we demonstrate that reduced norepinephrine signaling is necessary for these increase

250 Without norepinephrine signaling, HFSCs enter deep quiescence by

251 We determined that norepinephrine stimulated mast cell degranulation and hi

252 ittle effect on astroglial responsiveness to norepinephrine, suggesting that ethanol suppresses their

253 alloids (balanced electrolyte solution), and norepinephrine support.

254 Further, the altered norepinephrine synthesis observed here may, in part, exp

255 terized catecholaminergic (dopamine [DA]- or norepinephrine-synthesizing) neurons in any spider speci

256 y in ageing and highlight the role of the LC norepinephrine system in the decline of cognition.

257 ts that sensitization of the locus coeruleus-norepinephrine system may underlie behavioral and autono

258 was associated with activity of the central norepinephrine system, estimated using pupilometry, for

259 vity of an 'arousal' network, related to the norepinephrine system.

260 se is activation of the locus coeruleus (LC)-norepinephrine system.

261 c neurotransmitters, such as epinephrine and norepinephrine, that are known to increase virulence in

262 Norepinephrine, the cornerstone vasopressor used in sept

263 Norepinephrine, the first-line vasopressor for septic sh

264 associated with a 2011 national shortage of norepinephrine, the first-line vasopressor for septic sh

265 Here we report that norepinephrine, through its actions on beta-adrenergic r

266 The Intraoperative Norepinephrine to Control Arterial Pressure (INPRESS) st

267 ate whether vasopressin could be superior to norepinephrine to improve outcomes in cancer patients wi

268 s the release of the stress response hormone norepinephrine to stimulate beta-adrenergic receptors, c

269 The locus coeruleus (LC) supplies norepinephrine to the brain, is one of the first sites o

270 The brainstem locus coeruleus (LC) supplies norepinephrine to the forebrain and degenerates in Alzhe

271 The results demonstrate that Norepinephrine tracks unexpected uncertainty on rapid ti

272 Therapeutic targeting of the norepinephrine transporter (NET) function with benzylgua

273 The norepinephrine transporter (NET) is essential for norepi

274 ds to the dopamine transporter (DAT) and the norepinephrine transporter (NET), to unravel its effects

275 at DAT (EC50 approximately 35 nM) and at the norepinephrine transporter (NET).

276 y with (131)I-mIBG, a substrate of the human norepinephrine transporter (NET-1), shows promising resp

277 e five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin t

278 thalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with o

279 , vesicular monoamine transporter 2, and the norepinephrine transporter.

280 BG is known to enter tumor cells through the norepinephrine transporter.

281 selectivity toward DAT versus serotonin and norepinephrine transporters than modafinil.

282 transporters (i.e., serotonin, dopamine, and norepinephrine transporters) have been implicated as pla

283 DHD), which blocks dopamine transporters and norepinephrine transporters, ameliorated the behavioral

284 Norepinephrine turnover in brown fat was reduced at both

285 iac and vascular response to epinephrine and norepinephrine underlies optimal management in catechola

286 inephrine transporter (NET) is essential for norepinephrine uptake at the synaptic terminals and adre

287 quarter of norepinephrine shortage in 2011, norepinephrine use among cohort patients declined from 7

288 al in 2011 during which the hospital rate of norepinephrine use decreased by more than 20% from basel

289 Healthcare Database with a baseline rate of norepinephrine use of at least 60% for patients with sep

290 eers were randomized to a 5-hour infusion of norepinephrine, vasopressin, or saline and intravenously

291 In VASST, vasopressin compared with norepinephrine was associated with improved 90-day morta

292 Norepinephrine was modestly increased while the ratio be

293 owth factor-1 were positively associated and norepinephrine was negatively associated with hindlimb w

294 utput was decreased during withdrawal, while norepinephrine was released in the vBNST during specific

295 Conclusions: Early norepinephrine was significantly associated with increas

296 urohormonal activation because the change in norepinephrine was superior (P=0.02) and all other neuro

297 lin-1 (ET-1), thromboxane analog U46619, and norepinephrine were mediated by ET(A), thromboxane, and

298 ctures with HFSCs and regulate HFSCs through norepinephrine, whereas APMs maintain sympathetic innerv

299 e hormones/neurotransmitters epinephrine and norepinephrine which are found in the nervous system and

300 artbeat of zebrafish larvae to verapamil and norepinephrine, which are known to affect cardiovascular